Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
OHTUVAYRE: selected primary-label renal guidance and limits
Product / population
Adult OHTUVAYRE nebulized inhalation suspension for COPD maintenance; not rescue treatment or an injectable product.
Renal method
Mild/moderate/severe categories; do not turn a supporting PK sample range into a dosing cutoff
Source revision
10/2026
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
OHTUVAYRE: source applicability and renal evidence limits
Severe impairment not evaluated; dialysis regimen not established here. The RX mirror is not independent corroboration of the matched label.
What to reconcile: Nebulized maintenance therapy, not rescue medication.
DailyMed / product prescribing information · Adult OHTUVAYRE nebulized inhalation suspension for COPD maintenance; not rescue treatment or an injectable product.
Renal method: Mild/moderate/severe categories; do not turn a supporting PK sample range into a dosing cutoff Source date: 10/2026 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Severe impairment not evaluated; dialysis regimen not established here.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Sections 8.7 and 12.3
Mild or moderate renal impairment requires no dose adjustment. Severe impairment has not been evaluated. The supporting PK sample range is not a validated severe-impairment dose threshold. These passages supply no dialysis regimen. Use the inhalation product and its labeled maintenance schedule, not acute-bronchospasm rescue dosing.
RDM72-ensifentrine-ohtuvayre-label-1 · Source locator: Sections 8.7 and 12.3
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
